C12N 15/1131
Against viruses
Official title: {against viruses}
C12N15/1131 (Against viruses) appears on 998 US grants and 1,494 published applications in this corpus.
Search patents in C12N- Granted patents
- 998
- Published applications
- 1,494
- Assignees
- 641
- Inventors
- 2,508
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 5 | 0 |
| 1993 | 7 | 0 |
| 1994 | 5 | 0 |
| 1995 | 6 | 0 |
| 1996 | 14 | 0 |
| 1997 | 47 | 0 |
| 1998 | 53 | 0 |
| 1999 | 35 | 0 |
| 2000 | 39 | 0 |
| 2001 | 23 | 5 |
| 2002 | 39 | 20 |
| 2003 | 21 | 64 |
| 2004 | 16 | 51 |
| 2005 | 3 | 76 |
| 2006 | 13 | 48 |
| 2007 | 12 | 43 |
| 2008 | 9 | 58 |
| 2009 | 12 | 71 |
| 2010 | 45 | 58 |
| 2011 | 40 | 58 |
| 2012 | 47 | 54 |
| 2013 | 35 | 47 |
| 2014 | 44 | 51 |
| 2015 | 46 | 66 |
| 2016 | 36 | 64 |
| 2017 | 46 | 67 |
| 2018 | 35 | 65 |
| 2019 | 51 | 72 |
| 2020 | 37 | 63 |
| 2021 | 36 | 60 |
| 2022 | 33 | 62 |
| 2023 | 22 | 96 |
| 2024 | 33 | 68 |
| 2025 | 29 | 70 |
| 2026 | 20 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Specific host factor of hepatitis B virus infection, and use thereof22 Sep 2026US 12,742,164 B2National Institute of Biological Sciences, Beijing
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Lipid nanoparticles and methods of use28 Jul 2026US 12,692,499 B2City of Hope
- Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers1 Oct 2026US 2026/0295071 A1Algipharma AS
- Oligonucleotides comprising segmented gap structures1 Oct 2026US 2026/0297584 A1Ausperbio Therapeutics Inc.
- Methods of treating chronic hepatitis b24 Sep 2026US 2026/0286361 A1GlaxoSmithKline Intellectual Property Development Limited
- Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same17 Sep 2026US 2026/0275347 A1The Board of Trustees of the Leland Stanford Junior University
- Method for reducing chlorophyll degradation in a plant17 Sep 2026US 2026/0275367 A1Zhejiang Wanli University
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Oligonucleotide therapeutic agent and method of making same726US 5,023,243 AMolecular Biosystems, Inc. · 1991
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996